Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | ACACA | Q13085 | 2/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201623 | 0.92 | APP (0.44) | APPFFAR1ACACBACACAPTGDR2 | |
| SCHEMBL1202425 | 0.90 | APP (0.41) | AKR1C3AKR1C2APPFFAR1PPARD | |
| SCHEMBL1203130 | 0.90 | APP (0.49) | AKR1C3AKR1C2APPFFAR1PPARD | |
| SCHEMBL1202655 | 0.87 | AKR1C3 (0.51) | AKR1C3AKR1C2APPPTGDR2PTGS2 | |
| SCHEMBL1202343 | 0.85 | APP (0.49) | APPPTGDR2 | |
| SCHEMBL1202689 | 0.85 | APP (0.47) | AKR1C3AKR1C2APPACACBACACA | |
| SCHEMBL1202952 | 0.85 | APP (0.45) | AKR1C3AKR1C2APPKEAP1NFE2L2 | |
| SCHEMBL1203009 | 0.84 | APP (0.44) | AKR1C3AKR1C2APPACACBACACA | |
| SCHEMBL1202974 | 0.84 | APP (0.43) | APPPTGDR2 | |
| SCHEMBL1202250 | 0.83 | BRD4 (0.46) | APPPTGDR2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2009036428-A2 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | AKR1C3 3717/4885AKR1C2 3410/4885APP 4/4885 |
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | AKR1C3 3717/4885AKR1C2 3410/4885APP 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.